




Searching News Database: Mucopolysaccharidosis II
HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
HSMN NewsFeed - 8 Aug 2007
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 24 Jul 2006
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Additional items found! 3

Members Archive contains
3 additional stories matching:
Mucopolysaccharidosis II
(Password required)
Mucopolysaccharidosis II
(Password required)